telephone icon+44 207 263 2509

map marker icon ONLINE OR 65 COMMERCIAL ST, LONDON E1 6BD

Cyrex Alzheimer’s Linx

£697.00 incl. VAT: £836.40

Description

Antigens Tested

Brain Proteins

Assessing reactivity to brain proteins beyond amyloid-beta and tau protein.

  • Tau Protein IgG
  • Amyloid-Beta Peptide IgG
  • Rabaptin-5 + Presenilin IgG
  • Alpha-Synuclein IgG

Growth Factors

Measuring immune reactivity to factors involved in neuronal regeneration.

  • Beta Nerve Growth Factor IgG
  • Brain Derived Neurotrophic Factor IgG
  • Neurotrophins IgG
  • Somatotropin IgG

Enteric Nerve, Enzymes and Neurological Peptides

Assessing immune reactivity to the communication pathway between the gut and the brain.

  • Enteric Nerve + Vasoactive Intestinal Peptide IgG
  • Transglutaminases IgG

Pathogens

Assessing immune reactivity to pathogens known to cross-react with amyloid-beta.

  • Oral Pathogens IgG
  • Enterococcus faecalis IgG
  • Escherichia coli CDT + Salmonella CDT IgG
  • Campylobacter jejuni CDT IgG
  • Herpes Type-1 IgG

Chemicals

Biomarkers for a collection of chemicals/heavy metals discovered to have associations to Alzheimer’s disease.

  • Aluminums IgG
  • Dinitrophenyl IgG
  • Ethyl + Methyl Mercury IgG
  • Phthalates IgG

Foods Cross-Reactive to Amyloid-Beta

8 out of 208 common foods, newly discovered to have a potential association with Alzheimer’s disease.

  • Egg Yolk, raw + cooked IgG
  • Lentil Lectin + Pea Lectin IgG
  • Tuna, canned IgG
  • Hazelnut Vicilin + Cashew Vicilin IgG
  • Scallops + Squid IgG
  • Caseins IgG
  • Alpha-Gliadin + Gliadin Toxic Peptide IgG
  • Non-Gluten Proteins IgG

Blood-Brain Barrier and Neurofilaments

Blood-Brain Barrier antibody biomarkers which assess the integrity of the blood-brain barrier.

  • Blood-Brain Barrier Protein + Claudin-5 IgG
  • Aquaporins IgG
  • Neurofilaments Proteins IgG

Clinical Use

  • Identifying asymptomatic individuals at greater risk for developing cognitive decline including Alzheimer’s disease or other neurological disorders.
  • Identifying reactivity to triggers of Alzheimer’s disease or other neurological disorders.
  • Identifying the early stages of neurodegenerative processes.
  • Monitoring the efficacy of lifestyle modifications for Alzheimer’s disease.

This Test Is Recommended for Patients Who:

  • Are interested in preventing the development of Alzheimer’s disease, cognitive decline or other neurological disorder.
  • Are exhibiting early signs of Alzheimer’s disease or other neurological disorder.
  • Have been diagnosed with Alzheimer’s disease.
  • Have a history of gastrointestinal disorders and/or diabetes.
  • Played high-impact sports.
  • Are immunoreactive against specific pathogens, chemicals and foods.
  • Those currently undergoing a Bredesen Protocol programme.